Polygenic risk-tailored screening for prostate cancer: A benefit–harm and cost-effectiveness modelling study

BACKGROUND: The United States Preventive Services Task Force supports individualised decision-making for prostate-specific antigen (PSA)-based screening in men aged 55–69. Knowing how the potential benefits and harms of screening vary by an individual’s risk of developing prostate cancer could infor...

Descripción completa

Detalles Bibliográficos
Autores principales: Callender, Tom, Emberton, Mark, Morris, Steve, Eeles, Ros, Kote-Jarai, Zsofia, Pharoah, Paul D. P., Pashayan, Nora
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6924639/
https://www.ncbi.nlm.nih.gov/pubmed/31860675
http://dx.doi.org/10.1371/journal.pmed.1002998

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6924639/
https://www.ncbi.nlm.nih.gov/pubmed/31860675
http://dx.doi.org/10.1371/journal.pmed.1002998

Ejemplares similares